CRIS Current Research Information System

RICCIUTI, BIAGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.469
NA - Nord America 1.562
EU - Europa 629
SA - Sud America 168
Continente sconosciuto - Info sul continente non disponibili 154
AF - Africa 53
OC - Oceania 5
Totale 6.040
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.477
VN - Vietnam 1.336
SG - Singapore 719
CN - Cina 666
HK - Hong Kong 260
IT - Italia 244
BD - Bangladesh 141
BR - Brasile 128
KR - Corea 107
IN - India 79
NL - Olanda 64
DE - Germania 61
FI - Finlandia 44
CA - Canada 39
IE - Irlanda 37
FR - Francia 32
JP - Giappone 30
SE - Svezia 25
BG - Bulgaria 23
MX - Messico 23
JO - Giordania 22
AR - Argentina 20
RU - Federazione Russa 20
TH - Thailandia 20
AT - Austria 18
ID - Indonesia 18
GB - Regno Unito 17
PH - Filippine 16
CI - Costa d'Avorio 11
PK - Pakistan 10
IQ - Iraq 9
CH - Svizzera 8
JM - Giamaica 8
PL - Polonia 8
TG - Togo 7
TR - Turchia 7
BE - Belgio 6
ZA - Sudafrica 6
AU - Australia 5
CL - Cile 5
CR - Costa Rica 5
LT - Lituania 5
SC - Seychelles 5
VE - Venezuela 5
EG - Egitto 4
MA - Marocco 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CO - Colombia 3
GR - Grecia 3
IL - Israele 3
KE - Kenya 3
MY - Malesia 3
PT - Portogallo 3
UZ - Uzbekistan 3
BY - Bielorussia 2
DZ - Algeria 2
EC - Ecuador 2
ES - Italia 2
HN - Honduras 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
SA - Arabia Saudita 2
SN - Senegal 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.887
Salva come PNG Salva come JPEG
Città #
Singapore 472
Ho Chi Minh City 424
Hanoi 315
Hong Kong 252
Hefei 217
Ashburn 213
San Jose 195
Santa Clara 172
Seoul 97
Beijing 84
Council Bluffs 80
Boardman 65
Bologna 54
Da Nang 44
Haiphong 41
Helsinki 41
Los Angeles 39
Dublin 37
New York 37
Quận Bình Thạnh 32
Buffalo 31
Hyderabad 30
Ninh Bình 24
Tokyo 24
Biên Hòa 23
Chicago 23
Sofia 23
Dallas 21
Milan 21
São Paulo 21
Thái Nguyên 21
Amman 20
Bengaluru 20
Ha Long 19
Lauterbourg 19
Rome 18
Nuremberg 17
Can Tho 16
Hải Dương 16
Shanghai 15
Falkenstein 14
Chandler 13
Redondo Beach 13
Bắc Ninh 12
Mexico City 12
Orem 12
Seattle 12
Abidjan 11
Frankfurt am Main 11
Guangzhou 11
Jakarta 11
San Francisco 11
Thành Phố Bà Rịa 11
Vinh 11
Quận Phú Nhuận 10
Vienna 10
Vũng Tàu 10
Điện Bàn 10
Bắc Giang 9
Montreal 9
Atlanta 8
Naples 8
North Charleston 8
The Dalles 8
Thái Bình 8
Tongling 8
Toronto 8
Bangkok 7
Cà Mau 7
Lomé 7
Quảng Ngãi 7
Quận Bốn 7
Turin 7
Wuhan 7
Zhengzhou 7
Bern 6
Brooklyn 6
Hòa Bình 6
Modena 6
Nam Định 6
Nanjing 6
Nha Trang 6
Quận Một 6
San Antonio 6
Uyen Hung 6
Valdagno di Trento 6
Verona 6
Warsaw 6
Amsterdam 5
Brasília 5
Chengdu 5
Foshan 5
Kingston 5
London 5
Mumbai 5
Phoenix 5
Phủ Lý 5
Quận Bảy 5
Rimini 5
Shenzhen 5
Totale 3.806
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 944
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 248
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 178
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 171
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 160
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 157
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 151
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 150
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 137
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 136
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 125
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 121
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 120
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 119
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 111
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 109
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 103
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 92
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 92
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 88
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 86
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 86
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 86
Non-small-cell lung cancer: how to manage RET-positive disease 85
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 81
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 80
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 76
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 76
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 76
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 75
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 72
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 71
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 70
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 69
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 66
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 66
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 65
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 64
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 62
Non-small-cell lung cancer: how to manage EGFR-mutated disease 61
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 60
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer 57
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 55
Antibody–drug conjugates for lung cancer in the era of personalized oncology 55
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 54
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 53
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC 52
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 52
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 49
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 48
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 47
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 45
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 44
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 43
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 43
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC 41
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 41
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 41
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 40
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer 39
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 37
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer 34
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 25
Totale 6.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202214 0 0 0 0 0 0 0 4 0 2 5 3
2022/2023204 3 8 0 9 7 4 3 14 73 34 20 29
2023/2024195 12 17 19 16 15 39 7 44 9 7 4 6
2024/20251.255 32 98 96 63 230 66 127 45 13 88 99 298
2025/20263.931 1.191 374 251 217 243 135 251 131 462 256 216 204
2026/2027441 238 169 34 0 0 0 0 0 0 0 0 0
Totale 6.040